AMENDMENT NO. 4 TO SPONSORED RESEARCH COLLABORATION AGREEMENTSponsored Research Collaboration Agreement • November 30th, 2011 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 4 to Sponsored Research Collaboration Agreement (“Amendment No. 4”) is entered into and effective as of October 24, 2011, by and between University Health Network, an Ontario corporation incorporated under the Toronto Hospital Act 1997, having a principal research office at 610 University Avenue, Suite 7-504, Toronto, Ontario, Canada MSG 2M9 (“UHN”), and VistaGen Therapeutics, Inc., a Nevada corporation having its principal address at 384 Oyster Point Blvd., Suite 8, South San Francisco, California 94080 (“VistaGen”).
SPONSORED RESEARCH COLLABORATION AGREEMENT BY AND BETWEEN THE INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL AND AFFINIA THERAPEUTICS INC.Sponsored Research Collaboration Agreement • November 24th, 2021 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
This SPONSORED RESEARCH COLLABORATION AGREEMENT (this “Agreement” is made as of June 22, 2021 (the “Effective Date”), by and between Affinia Therapeutics Inc., having its principal offices at 43 Foundry Ave., Suite 120, Waltham, MA 02453 (“Affinia”) and The Institute of Molecular and Clinical Ophthalmology Basel with an address at Mittlere Strasse 91, CH-4031 Basel, Switzerland (“IOB”). Affinia and IOB are referred to individually as a “Party” and collectively as the “Parties”.
SPONSORED RESEARCH COLLABORATION AGREEMENT By and Between University Health Network, an Ontario corporation and VistaGen Therapeutics, Inc., a California corporationSponsored Research Collaboration Agreement • May 16th, 2011 • Excaliber Enterprises, Ltd. • Retail-catalog & mail-order houses
This "Agreement" is entered into as of , 2007 (the "Effective Date") by and between University Health Network, an Ontario corporation incorporated under the Toronto Hospital Act 1997, having a principal research office at 610 University Avenue, Ste. 7-504, Toronto, Ontario, Canada M5G 2M9 ("UHN") and VistaGen Therapeutics, Inc., a California corporation, having its address at 384 Oyster Point Blvd., Suite 8, South San Francisco, California 94080 ("VistaGen").
FIRST AMENDMENT TO SPONSORED RESEARCH COLLABORATION AGREEMENTSponsored Research Collaboration Agreement • October 22nd, 2008 • Combinatorx, Inc • Pharmaceutical preparations • Massachusetts
FIRST AMENDMENT TO SPONSORED RESEARCH COLLABORATION AGREEMENT (this "Amendment"), effective as of October 20, 2008, by and between CombinatoRx, Incorporated, a Delaware corporation (hereinafter "CombinatoRx"), having its principal place of business located at 245 First Street, Sixteenth Floor, Cambridge, MA 02142, and DART Therapeutics, LLC (hereinafter "Sponsor") with a principal place of business at 4 Button Ball Lane, South Egremont, MA 01258 (CombinatoRx and Sponsor are sometimes hereinafter referred to collectively as the "Parties" or individually as a "Party");
SPONSORED RESEARCH COLLABORATION AGREEMENTSponsored Research Collaboration Agreement • October 8th, 2020 • Texas
This Agreement is made this 1st day of May 2020 (the “Effective Date”), between The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 (“MD Anderson”), a member institution of The University of Texas System (“UTSystem”), Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (“BCM”), Texas A&M University Health Science Center, 301 Old Main Dr., College Station, Texas 77843 (“TAMHSC”), a health related entity of Texas A&M University, a member of the The Texas A&M University System (“TAMUS”) and Cedars-Sinai Medical Center 8700 Beverly Blvd., Los Angeles, CA 90048 (“CSMC”). Each party is hereinafter referred to as a “Collaborator.” The Collaborators hereby agree as follows:
